RARE Ultragenyx Pharmaceutical Inc

Price (delayed)

$76.01

Market cap

$5.18B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.26

Enterprise value

$5.03B

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of ...

Highlights
The revenue has surged by 67% year-on-year
The company's gross profit has surged by 63% YoY
The quick ratio has increased by 42% YoY but it has decreased by 18% QoQ
The equity has increased by 40% year-on-year but it has declined by 4% since the previous quarter
Ultragenyx Pharmaceutical's net income has decreased by 39% YoY
RARE's EPS is down by 20% year-on-year

Key stats

What are the main financial stats of RARE
Market
Shares outstanding
68.16M
Market cap
$5.18B
Enterprise value
$5.03B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.52
Price to sales (P/S)
14.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.98
Earnings
Revenue
$359.56M
EBIT
-$354.48M
EBITDA
-$341.65M
Free cash flow
-$425.79M
Per share
EPS
-$5.26
Free cash flow per share
-$6.27
Book value per share
$13.76
Revenue per share
$5.3
TBVPS
$19.29
Balance sheet
Total assets
$1.48B
Total liabilities
$551.13M
Debt
$44.04M
Equity
$933.67M
Working capital
$710.95M
Liquidity
Debt to equity
0.05
Current ratio
6.23
Quick ratio
5.61
Net debt/EBITDA
0.45
Margins
EBITDA margin
-95%
Gross margin
95%
Net margin
-98.9%
Operating margin
-104.6%
Efficiency
Return on assets
-22.4%
Return on equity
-34.6%
Return on invested capital
-38.6%
Return on capital employed
-26.3%
Return on sales
-98.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RARE stock price

How has the Ultragenyx Pharmaceutical stock price performed over time
Intraday
-3.93%
1 week
-0.63%
1 month
-11.62%
1 year
-38.77%
YTD
-45.09%
QTD
-15.72%

Financial performance

How have Ultragenyx Pharmaceutical's revenue and profit performed over time
Revenue
$359.56M
Gross profit
$341.58M
Operating income
-$376.05M
Net income
-$355.58M
Gross margin
95%
Net margin
-98.9%
The revenue has surged by 67% year-on-year
The company's gross profit has surged by 63% YoY
Ultragenyx Pharmaceutical's net income has decreased by 39% YoY
The company's operating margin rose by 32% YoY but it fell by 12% QoQ

Growth

What is Ultragenyx Pharmaceutical's growth rate over time

Valuation

What is Ultragenyx Pharmaceutical stock price valuation
P/E
N/A
P/B
5.52
P/S
14.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.98
RARE's EPS is down by 20% year-on-year
The equity has increased by 40% year-on-year but it has declined by 4% since the previous quarter
RARE's price to book (P/B) is 20% less than its last 4 quarters average of 6.9
The P/S is 100% lower than the 5-year quarterly average of 3881.4 and 35% lower than the last 4 quarters average of 22.2
The revenue has surged by 67% year-on-year

Efficiency

How efficient is Ultragenyx Pharmaceutical business performance
RARE's return on sales is up by 16% year-on-year
The ROE is up by 12% year-on-year and by 5% since the previous quarter
The company's return on invested capital rose by 8% YoY and by 7% QoQ
The return on assets has declined by 8% year-on-year but it has increased by 2.2% since the previous quarter

Dividends

What is RARE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RARE.

Financial health

How did Ultragenyx Pharmaceutical financials performed over time
The total assets is 169% more than the total liabilities
The current ratio is up by 44% YoY but it is down by 17% QoQ
The quick ratio has increased by 42% YoY but it has decreased by 18% QoQ
Ultragenyx Pharmaceutical's debt is 95% less than its equity
The equity has increased by 40% year-on-year but it has declined by 4% since the previous quarter
Ultragenyx Pharmaceutical's debt has increased by 20% YoY but it has decreased by 4.6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.